April 14, 2021
Business News

Publication of a New Study on Voluntis by Brokerage Firm Bryan, Garnier & Co

CAMBRIDGE, Mass. & PARIS–()–Regulatory News:

Voluntis (Paris:ALVTX) (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960), a leader in the field of digital therapeutics, announces that Bryan, Garnier & Co, a leading pan-European investment bank dedicated to growth companies, has just updated its coverage of the company in a study entitled “A front-runner in Digital Therapeutics”.

The publication of this new study is in line with the objective of increasing Voluntis’ visibility, broadening its investor base and updating the consensus of financial analysts who follow the stock alongside brokerage firm Gilbert Dupont.

The executive summary of Bryan, Garnier & Co analysis note is available via the following…

Click here to view the original article.

Related Posts

You might also like ...

Spark NZ Selects Calabrio as Part of Unified Front Line Initiative
AlixPartners Disruption Index Reveals That Business Leaders Don’t Consider COVID-19 to Be the Most Disruptive Force Impacting Their Organization
Germany’s Supreme Court Rules in Solvay’s Favor on Patent Case With Neo